http://www.ultragenyx.com
Ultragenyx Pharmaceutical Inc. Company Intro
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
Industry
Healthcare
Ultragenyx Pharmaceutical Inc. Headquaters
60 Leveroni Court
Novato,94949
United States
Ultragenyx Pharmaceutical Inc. Share price
14 Sep 2022 10:06 GMT
$47.63
-1.15 (-2.36 %)
Ultragenyx Pharmaceutical Inc. Market cap
$3.123 B
WMC RANKING
2022
Ultragenyx Pharmaceutical Inc. # 49
BiotechnologyLatest Ultragenyx Pharmaceutical Inc. News
27 Sep 2022
Ornithine-Transcarbamylase Deficiency Market Size And ...
PhaseRx Inc; Ultragenyx Pharmaceutical Inc; Promethera Biosciences SA; Unicyte AG; Lucane Pharma SA; Translate Bio Inc; Selecta Biosciences Inc. Market...
26 Sep 2022
Surprising Analyst 12-Month Target For IWR
iShares Russell Mid-Cap ETF, IWR, $63.62 ; Ginkgo Bioworks Holdings Inc, DNA, $2.80 ; Ultragenyx Pharmaceutical Inc, RARE, $41.50 ; Upstart Holdings Inc, UPST...
25 Sep 2022
Solid Biosciences (NASDAQ:SLDB) & Aerie Pharmaceuticals ...
The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne...
WMC Market Score
WMC Market to Revenue Score
Ultragenyx Pharmaceutical Inc. Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| Ultragenyx Pharmaceutical Inc. | USD | $334,116 | $635,316 | $-203,682 | $31,230B | 49 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $754,300B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $713,610B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ | 3 |
| Incyte Corporation | USD | $2,702,913 | $2,048,306 | $478,480 | $150,520B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Ultragenyx Pharmaceutical Inc. Social Followers vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. Post vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| Ultragenyx Pharmaceutical Inc. | 3.63 | 0 | 0 | 0 | 0 | 0 | 0.14 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 22 | 0 | 0 | 28.52 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 33 | 0 | 0 | 34.78 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 22 | 0 | 0 | 100 |
| Incyte Corporation | 29.39 | 5.03 | 0.04 | 100 | 0 | 0 | 47.37 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
